Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

555 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver.
Urabe M, Hikita H, Saito Y, Kudo S, Fukumoto K, Mizutani N, Myojin Y, Doi A, Sato K, Sakane S, Makino Y, Kodama T, Sakamori R, Tatsumi T, Takehara T. Urabe M, et al. Among authors: doi a. Hepatol Commun. 2022 Feb;6(2):411-422. doi: 10.1002/hep4.1815. Epub 2021 Sep 28. Hepatol Commun. 2022. PMID: 34585534 Free PMC article.
Persistent hepatocyte apoptosis promotes tumorigenesis from diethylnitrosamine-transformed hepatocytes through increased oxidative stress, independent of compensatory liver regeneration.
Nozaki Y, Hikita H, Tanaka S, Fukumoto K, Urabe M, Sato K, Myojin Y, Doi A, Murai K, Sakane S, Saito Y, Kodama T, Sakamori R, Tatsumi T, Takehara T. Nozaki Y, et al. Among authors: doi a. Sci Rep. 2021 Feb 9;11(1):3363. doi: 10.1038/s41598-021-83082-7. Sci Rep. 2021. PMID: 33564095 Free PMC article.
Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort.
Doi A, Sakamori R, Tahata Y, Urabe A, Morishita N, Yamada R, Furuta K, Kodama T, Hikita H, Yakushijin T, Ohkawa K, Kaneko A, Imai Y, Tatsumi T, Takehara T. Doi A, et al. Hepatol Res. 2017 Dec;47(13):1438-1444. doi: 10.1111/hepr.12919. Epub 2017 Aug 1. Hepatol Res. 2017. PMID: 28585404
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.
Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Miyazaki M, Ohkawa K, Mita E, Iio S, Nozaki Y, Yakushijin T, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Maesaka K, et al. Among authors: doi a. Hepatol Res. 2022 Jul;52(7):630-640. doi: 10.1111/hepr.13771. Epub 2022 Apr 25. Hepatol Res. 2022. PMID: 35417606
Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
Shirai K, Hikita H, Sakane S, Narumi R, Adachi J, Doi A, Tanaka S, Tahata Y, Yamada R, Kodama T, Sakamori R, Tatsumi T, Mita E, Tomonaga T, Takehara T. Shirai K, et al. Among authors: doi a. PLoS One. 2022 Jul 7;17(7):e0271020. doi: 10.1371/journal.pone.0271020. eCollection 2022. PLoS One. 2022. PMID: 35797333 Free PMC article.
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Doi A, Hikita H, Kai Y, Tahata Y, Saito Y, Nakabori T, Yamada R, Kodama T, Sakamori R, Murayama A, Nitta S, Asahina Y, Suemizu H, Tatsumi T, Kato T, Takehara T. Doi A, et al. J Gastroenterol. 2019 May;54(5):449-458. doi: 10.1007/s00535-018-01541-x. Epub 2019 Jan 25. J Gastroenterol. 2019. PMID: 30684016
555 results